| 35.72 -0.565 (-1.56%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 48.43 | 1-year : | 56.57 |
| Resists | First : | 41.47 | Second : | 48.43 |
| Pivot price | 35.8  |
|||
| Supports | First : | 31.71 | Second : | 25.69 |
| MAs | MA(5) : | 36.23 |
MA(20) : | 34.18 |
| MA(100) : | 25.09 |
MA(250) : | 22.61 |
|
| MACD | MACD : | 2.3 |
Signal : | 2.6 |
| %K %D | K(14,3) : | 48.1 |
D(3) : | 54.2 |
| RSI | RSI(14): 59 |
|||
| 52-week | High : | 41.47 | Low : | 14.06 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NAMS ] has closed above bottom band by 49.2%. Bollinger Bands are 60.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 17 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 36.97 - 37.15 | 37.15 - 37.32 |
| Low: | 34.6 - 34.82 | 34.82 - 35.04 |
| Close: | 35.32 - 35.67 | 35.67 - 36.02 |
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Tue, 21 Oct 2025
NewAmsterdam Pharma (NAMS) Stock Analysis: A Biotech Powerhouse with 740% Revenue Growth and Strong Buy Ratings - DirectorsTalk Interviews
Mon, 20 Oct 2025
H.C. Wainwright assumes coverage on NewAmsterdam Pharma stock with Buy rating - Investing.com
Sun, 19 Oct 2025
(NAMS) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Sat, 11 Oct 2025
NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know - ts2.tech
Tue, 07 Oct 2025
NewAmsterdam Pharma Company N.V. (NAMS) Soars 5.9%: Is Further Upside Left in the Stock? - Yahoo Finance
Wed, 24 Sep 2025
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 113 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 105.8 (%) |
| Shares Short | 7,640 (K) |
| Shares Short P.Month | 7,500 (K) |
| EPS | -1.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.92 |
| Profit Margin | -259 % |
| Operating Margin | -186.2 % |
| Return on Assets (ttm) | -17.2 % |
| Return on Equity (ttm) | -28.5 % |
| Qtrly Rev. Growth | 740 % |
| Gross Profit (p.s.) | 0.56 |
| Sales Per Share | 0.56 |
| EBITDA (p.s.) | -1.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -124 (M) |
| Levered Free Cash Flow | -85 (M) |
| PE Ratio | -22.48 |
| PEG Ratio | 0 |
| Price to Book value | 5.16 |
| Price to Sales | 62.86 |
| Price to Cash Flow | -32.43 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|